With its purchase of SeqWright for an undisclosed sum, GE is investing more in personalized medicine, The Wall Street Journal's Health Blog says. SeqWright is a contract genomic research organization that offers sequencing services among others, and GE says the company will supplement its 2009 purchase of Clarient, a cancer diagnostics company, for $580 million. Pharmaceutical companies are increasingly looking for targeted therapies, the Journal says, adding that clinicians then will have to be able determine patients' genetic profiles to match to the best therapies. "That's where GE hopes to come in, by developing technologies to better identify the genetic profile of cancers and other illnesses," the Journal notes.
"Combining the expertise and capabilities of the two companies will enable GE Healthcare to offer a substantially wider range of services to the biopharmaceutical, diagnostic and research industries and eventually to patients and health care providers," say GE Healthcare president and CEO Pascale Witz in a statement.
Our sister publication GenomeWeb Daily News has more on the deal here.